Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on March 21, 2023, reporting events occurring on that date. The filing concerns Lucid Diagnostics Inc., a majority-owned subsidiary of Pavmed Inc., and details the consummation of a private placement financing transaction.
Key Financial Metrics
The filing reports the sale of a Senior Secured Convertible Note with an initial principal amount of up to $11,111,110. The transaction was executed between Lucid Diagnostics Inc. and an accredited investor. The filing does not provide specific data on revenue, profit, cash flow, operating margins, existing debt levels, or liquidity ratios for the reporting period.
Material Changes
On March 21, 2023, Lucid Diagnostics Inc. consummated the sale of the Note previously announced on March 13, 2023. In connection with this consummation, the following material agreements were executed:
- A Registration Rights Agreement with the investor.
- A Voting Agreement between the investor and Pavmed Inc.
These actions represent a material modification to the rights of security holders and the creation of a direct financial obligation.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosures associated with the new debt instrument and voting agreements. The details of the Registration Rights Agreement and Voting Agreement are incorporated by reference from a concurrent Form 8-K filed by Lucid Diagnostics Inc. on March 24, 2023.
Investor Verification Checklist
- Verify the full terms of the Senior Secured Convertible Note, including interest rates, conversion price, maturity date, and covenants.
- Review the Registration Rights Agreement to understand the investor's ability to force registration of the securities.
- Examine the Voting Agreement to determine the extent of the investor's influence on corporate governance.
- Confirm the identity of the accredited investor and any related party relationships.
- Assess the impact of the $11,111,110 principal amount on the company's overall capital structure and leverage.